Market capitalization | $313.01m |
Enterprise Value | $148.04m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.62 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-100.03m |
Free Cash Flow (TTM) Free Cash Flow | $-86.29m |
Cash position | $190.27m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
9 Analysts have issued a Solid Biosciences Inc. forecast:
9 Analysts have issued a Solid Biosciences Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -2.74 -2.74 |
1%
1%
|
|
EBITDA | -97 -97 |
8%
8%
|
EBIT (Operating Income) EBIT | -100 -100 |
8%
8%
|
Net Profit | -91 -91 |
0%
0%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy. It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Arnold, Annie Ganot and Gilad David Hayeem in March 2013 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Alexander Cumbo |
Employees | 88 |
Founded | 2013 |
Website | www.solidbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.